Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

about

A novel LIPS assay for insulin autoantibodies.

P2860

Q48300084-5121E2EF-9EAB-4FEE-A4E9-1F575D1D799B

P2860

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Item

http://www.wikidata.org/entity/Q38837965

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Do Electrochemiluminescence As ...... dy-Positive TrialNet Subjects?

@en

type

Item

label

Do Electrochemiluminescence As ...... dy-Positive TrialNet Subjects?

@en

prefLabel

Do Electrochemiluminescence As ...... dy-Positive TrialNet Subjects?

@en

P1476

Do Electrochemiluminescence As ...... dy-Positive TrialNet Subjects?

@en

P2093

Aaron Michels

http://www.w3.org/2001/XMLSchema#string

Alexandra Fouts

http://www.w3.org/2001/XMLSchema#string

Andrea K Steck

http://www.w3.org/2001/XMLSchema#string

Dongmei Miao

http://www.w3.org/2001/XMLSchema#string

Jay Sosenko

http://www.w3.org/2001/XMLSchema#string

Jeffrey Krischer

http://www.w3.org/2001/XMLSchema#string

Laura Pyle

http://www.w3.org/2001/XMLSchema#string

Liping Yu

http://www.w3.org/2001/XMLSchema#string

Peter Gottlieb

http://www.w3.org/2001/XMLSchema#string

Type 1 Diabetes TrialNet Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Type 1 diabetes

The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).

Type 1 Diabetes TrialNet--an international collaborative clinical trials network

Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young.

Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk.

Development of autoantibodies in the TrialNet Natural History Study

Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).

Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay

P304

1738-1744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC16-0302

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27456836

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

autoantibody

P932

5033080

http://www.w3.org/2001/XMLSchema#string

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

about

P2860

P2860

Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932